Search

Metalyse

Metalyse

tenecteplase

Manufacturer:

Boehringer Ingelheim

Distributor:

DKSH
Concise Prescribing Info
Contents
Tenecteplase
Indications/Uses
Thrombolytic treatment of acute MI initiated as soon as possible after symptom onset.
Click to view Metalyse detailed prescribing information
Dosage/Direction for Use
Patient ≥90 kg 50 mg (10,000 U), ≥80 to <90 kg 45 mg (9,000 U), ≥70 to <80 kg 40 mg (8,000 U), ≥60 to <70 kg 35 mg (7,000 U), <60 kg 30 mg (6,000 U). Given as single IV bolus over 5-10 sec.
Click to view Metalyse detailed prescribing information
Overdosage
View Metalyse overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity to tenecteplase, gentamicin. Significant bleeding disorder (present or w/in past 6 mth), known haemorrhagic diathesis; history of CNS damage ie, neoplasm, aneurysm, intracranial or spinal surgery; severe uncontrolled arterial HTN; major surgery, parenchymal organ biopsy or significant trauma w/in past 2 mth, recent head or cranial trauma; prolonged or traumatic CPR (>2 min) w/in past 2 wk; active peptic ulceration; arterial aneurysm, arterial/venous malformation; neoplasm w/ increased bleeding risk; acute pericarditis &/or subacute bacterial endocarditis; acute pancreatitis; haemorrhagic stroke or stroke of unknown origin; ischaemic stroke or transient ischaemic attack in the preceding 6 mth. Patients receiving oral anticoagulants. Severe hepatic dysfunction including hepatic failure, cirrhosis, portal HTN (oesophageal varices) & active hepatitis.
Click to view Metalyse detailed prescribing information
Special Precautions
Discontinue use if anaphylactoid reaction occurs. Not to be given in primary percutaneous coronary intervention. Increased risk of bleeding; thromboembolic events. Arrhythmias. Systolic BP >160 mmHg; recent GI or genitourinary bleeding (w/in past 10 days); recent IM inj (w/in past 2 days); low body wt <60 kg; cerebrovascular disease. As primary coronary recanalization treatment, patient should be transferred immediately to coronary intervention-capable facility for angiography & timely coronary intervention w/in 6-24 hr. Avoid use of rigid catheters, IM inj. Primary percutaneous coronary intervention. Concomitant use w/ oral anticoagulants; glycoprotein IIb/IIIa antagonists. Pregnancy & lactation. Childn. Elderly >75 yr.
Click to view Metalyse detailed prescribing information
Adverse Reactions
Anaphylactoid reaction; intracranial haemorrhage; eye haemorrhage; reperfusion arrhythmias, pericardial haemorrhage; haemorrhage, embolism; epistaxis, pulmonary haemorrhage; GI & retroperitoneal haemorrhage, nausea, vomiting; ecchymosis; urogenital haemorrhage; inj & puncture site haemorrhage; decreased BP, increased body temp; fat embolism.
Drug Interactions
Increased risk of bleeding w/ medicinal products affecting coagulation or altering platelet function.
Click to view Metalyse detailed prescribing information
Caution For Usage
For caution against possible variation of physical aspect of medicine... Click to view Metalyse detailed prescribing information
Storage
View Metalyse storage conditions for details to ensure optimal shelf-life.
Description
View Metalyse description for details of the chemical structure and excipients (inactive components).
Action
View Metalyse mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AD11 - tenecteplase ; Belongs to the class of enzymes. Used in the treatment of thrombosis.
Presentation/Packing
Form
Metalyse powd for inj (vial) 50 mg (10,000 U)
Packing/Price
(+ WFI (pre-filled syringe) 10 mL x 1's) 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in